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Minor neurological signs are subtle deficits in sensory in-
tegration, motor coordination, and sequencing of complex 
motor acts present in excess in the early stages of psy-
chosis. Still, it remains unclear whether at least some of 
these signs represent trait or state markers for psychosis 
and whether they are markers of long-term disease out-
come of clinical utility. We examined the relationship be-
tween neurological function at illness onset assessed with 
the Neurological Evaluation Scale and subsequent ill-
ness course in 233 patients from AESOP-10 (Aetiology 
and Ethnicity in Schizophrenia and Other Psychoses), a 
10-year follow-up study of a population-based cohort of 
individuals recruited at the time of their first episode of 
psychosis in the United Kingdom. In 56 of these patients, 
we also explored changes in neurological function over 
time. We included a group of 172 individuals without psy-
chosis as controls. After 10 years, 147 (63%) patients had 
developed a non-remitting course of illness, and 86 (37%) 
a remitting course. Already at first presentation, patients 
who developed a non-remitting course had significantly 
more primary, motor coordination, and total signs than 
both remitting patients and healthy controls. While Motor 
Coordination signs did not change over time, rates of 
Primary, Sensory Integration, and Total signs increased, 
independently of illness course type. These findings suggest 
that motor coordination problems could be a useful early, 
quick, and easily detectable marker of subsequent clinical 
outcome. With other motor abnormalities, a measure of 
motor incoordination could contribute to the identification 
of the most vulnerable individuals, who could benefit from 
targeted and more assertive treatment approaches.
Key words:  neurological signs/first-episode psychosis/ 
clinical outcome/remission
Introduction
Minor neurological signs are subtle deficits in sensory in-
tegration, motor coordination, and sequencing of com-
plex motor acts present in excess in the early stages of 
affective and nonaffective psychoses, and even in drug-
naïve patients.1 Still, it remains unclear whether these 
signs represent trait or state markers of psychosis and 
whether they are markers of long-term disease outcome 
of clinical utility.
Minor neurological signs are already present at illness 
onset with moderate to large effect sizes of  impairment 
in patients and first-degree relatives with no psychosis2 
and may even precede the onset of  psychosis, suggesting 
that they have a neurodevelopmental origin. As such, 
they may represent illness traits and endophenotypes.3,4 
This is further supported by evidence that although often 
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described as “soft,” these signs have consistent brain 
morphometric and functional correlates, including the 
precentral and postcentral gyri, premotor and frontal 
gyri, inferior parietal lobule, temporal gyri and insula, 
thalamus and basal ganglia, and cerebellum.5–10 Crucially, 
recent studies have also shown that sensorimotor dys-
function, proposed to be a primary domain of  psychosis, 
is associated with aberrant connectivity of  sensorimotor 
areas,11 iron loadings in the left accumbens,12 and vol-
umes of  medulla oblongata and pons.13 Furthermore, 
multimodal imaging data have shown that gray matter 
volume alterations co-occur with aberrant brain ac-
tivity in cortical and cerebellar systems subserving sen-
sorimotor dynamics and psychomotor organization, 
pointing to a defined pathophysiological substrate for 
sensorimotor dysfunctions and contributing to their def-
inition as potential biomarkers for psychosis.14
Still, whether neurological signs, and sensorimotor 
dysfunction in particular, at illness onset are a marker 
of long-term clinical and functional psychosis outcome 
remains to be established. Only 2 studies have explored 
their ability to predict outcome 10  years after illness 
onset, but neither evaluated their stability over time.15,16 
In those, Cuesta and colleagues15 found that signs score 
6 months after onset predicted poorer psychosocial func-
tioning, while White and colleagues16 found that signs at 
onset just predicted service dependency and only in pa-
tients with schizophrenia or schizoaffective disorder they 
predicted functional outcome.
More studies have evaluated neurological signs in rela-
tion to shorter-term outcomes, with some also exploring 
their trajectories, with inconsistent results, possibly due 
to inclusion of small and heterogeneous clinical samples 
and use of different neurological scales and outcome cri-
teria. The study with the longest follow-up evaluated neu-
rological signs trajectories over 5 years in 17 first-episode 
psychosis patients, finding that, while total neurological 
signs did not change, baseline primitive reflexes predicted 
subsequent poorer functional outcome.17 Other, shorter 
longitudinal studies also found no change in signs over 
time in first-episode patients, although they reported 
higher rates in association with more negative symp-
toms,18,19 higher antipsychotic dose,20 or improvement in 
psychopathology.21 In contrast, others found an increase 
in signs, for  example, in patients with a non-remitting 
illness over 220 and 5  years.22 Finally, several have also 
described a decrease in signs after illness onset, with a 
meta-analysis reporting that 14 out of 17 studies observed 
a decrease in signs over time in parallel with symptomatic 
remission.23 This was replicated recently in a large study 
of 349 patients, where a reduction in signs over 1  year 
correlated with an improvement in psychopathology 
and functioning, and rates at baseline predicted lack of 
treatment response.24 Of note, several studies reported 
that such reductions are more evident for sensorimotor 
signs21,25 in association with better clinical outcomes at 
1 year25 and 6 months,26 and even in children and adoles-
cents with early onset psychosis.27
Taken together, these findings confirm the significance 
of neurological signs, and particularly of sensorimotor 
deficits as one of the core dimensions of psychosis.28 
Motor signs are easily quantifiable, and their potential 
link with illness outcomes makes them useful candidate 
markers for the prediction of long-term trajectories of 
psychosis course.
In this study, we examined the relationship between 
multiple domains of neurological function at psychosis 
onset and 10-year outcomes. We additionally examined 
change in signs during this time in a subset of these pa-
tients. To our knowledge, this is the first, large longitu-
dinal study (n  =  233 patients) to examine neurological 
function at first episode of any psychosis across multiple 
functional domains and over a long duration of illness. 
We hypothesized that higher motor neurological signs at 
onset and their persistence over time would be associated 
with a non-remitting illness course over the first 10 years 
of illness, reflective of their potential neurodevelopmental 
origin and of their role as early markers of long-term ill-
ness severity.
Methods
This study was conducted as part of  the Aetiology 
and Ethnicity in Schizophrenia and Other Psychoses 
(AESOP-10) study, a 10-year follow-up of  a cohort 
of  557 patients, who consecutively presented to sec-
ondary mental health services in South East London, 
Nottingham, and Bristol (United Kingdom) for the first 
episode of  a functional psychotic illness (International 
Classification of  Disease [ICD-10] F10–19; F20–29; 
and F-30–39, psychotic coding).29 A detailed overview 
of  the follow-up procedures in the AESOP-10 study 
has been published elsewhere.30,31 The study also re-
cruited a group of  172 individuals without psychosis, 
aged 16–64 years, as a control group. All controls were 
screened for the presence of  psychotic symptoms with 
the Psychosis Screening Questionnaire32 and excluded 
if  they rated positively. All participants gave written 
consent and ethical approval was granted by the local 
Ethical Committee.
Baseline Assessment
At baseline, sociodemographic and clinical information 
were obtained for all subjects. Handedness was assessed 
with the Annett Hand Preference Questionnaire.33 
Premorbid Intelligence Quotient (IQ) was estimated 
with the National Adult Reading Test (NART)34 and 
current full-scale IQ was assessed using a shortened 
form of  revised Wechsler Adult Intelligence Scale 
(WAIS-R). For patients, diagnoses were made ac-
cording to the ICD-10 Criteria29 using the Schedules 
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for Clinical Assessment in Neuropsychiatry (SCAN)35 
based on consensus meetings with senior clinicians. 
Age of  illness onset was evaluated with the Personal 
and Psychiatric History Schedule36 based on interviews 
with the patient, a close relative, and clinical notes. 
Duration of  untreated illness was defined as the period 
in weeks from the onset of  psychotic phenomena to first 
contact with statutory mental health services. Duration 
of  illness was then defined as the time between onset of 
symptoms and time of  assessment. Antipsychotic type 
and dose (in chlorpromazine equivalents) were also 
recorded.
Follow-up Assessment and Illness Course
Information on course of  illness and symptom his-
tory were obtained retrospectively at follow-up using 
an extended version of  the World Health Organization 
(WHO) Life Chart37 based on case notes and clinical 
interview with patients and treating clinicians when-
ever possible. In interviews, we used significant anchor 
dates to assist recall and, as appropriate, interviews 
were structured around key events, such as hospital 
admissions. The SCAN35  criteria were used to estab-
lish the absence or presence of  psychotic symptoms 
over the follow-up period, consistent with WHO and 
other long-term outcome studies.38 Following the 
Schizophrenia Working Group Remission criteria,39 we 
adopted a 6-month period for establishing remission on 
the basis of  absence of  overt psychotic symptoms (op-
erationalized as score of  2 or 3 on Rating Scale 2 in 
the SCAN; 0  =  absence, 1  =  symptom occurred, but 
fleeting, 2 = symptom definitely present, 3 = symptom 
present more or less continuously). From the WHO Life 
Chart, we used illness course type to classify patients 
into “non remitting,” those with a more severe course 
(in the Life Chart, those with a continuous or inter-
mediate illness course, the former defined as having no 
periods of  symptom remission greater than 6 months, 
and the latter as having at least one illness episode and 
one period of  remission greater than 6 months) or “re-
mitting,” those with a more benign course (in the Life 
Chart, those with an episodic illness course, defined as 
having one or more periods of  remission greater than 
6  months and no episode of  psychosis, including the 
first one, lasting 6  months or more). Level of  func-
tioning was assessed using the Global Assessment of 
Functioning (GAF),40 which rates psychological, so-
cial, and occupational functioning. We recorded the 
number of  weeks of  treatment with antipsychotics from 
starting to stopping medications across the whole fol-
low-up through face-to-face interviews and evaluation 
of  patients’ records. We also estimated the proportion 
of  the time patients could be considered adherent to 
medications over the follow-up using clinical notes and 
the WHO Life Chart.
Neurological Signs
Neurological function was assessed at baseline and at 
follow-up with the expanded and previously validated 
version of Neurological Evaluation Scale (NES).41,42 For 
individuals with first-episode psychosis, the first assess-
ment of neurological abnormalities was performed as 
soon as possible after initial presentation. The expanded 
version of NES is a structured scale providing scores 
in 4 subscales reflecting different functional areas and 
demonstrating good construct validity41,43: (1) primary 
neurological dysfunction (dysfunction that can be identi-
fied by a standard neurological examination); (2) sensory 
integration dysfunction (dysfunction apparent in the inte-
gration of sensory information); (3) motor coordination 
dysfunction (reflecting signs of motor incoordination); 
(4) motor sequencing dysfunction (reflecting the ability 
to perform complex motor sequences).
Scores for the items present in the original NES (in-
cluded in the 3 subscales Sensory Integration, Motor 
Coordination, and Motor Sequencing) were left un-
changed (from 0 = no abnormality to 2 = marked im-
pairment, except for the snout and suck reflexes, scored 
as either 0 or 2). The remaining items (in the Primary 
signs subscale), were scored as 0  =  no abnormality; 
1  =  intermediate criterion; 2  =  clearly abnormal/
marked impairment.42 Minor neurological signs were 
rated by physicians blind to diagnosis reaching a good 
interrater reliability (r = .87 to .96). Each subscale was 
analyzed separately in order to provide a better rep-
resentation of  the different neurological dysfunction 
than the global score. We evaluated extrapyramidal 
symptoms with the Simpson–Angus Rating Scale,44 ak-
athisia with the Barnes rating scale,45 and tardive dys-
kinesia with the Abnormal Involuntary Movement in 
Schizophrenia Scale (AIMS).46
Statistical Analysis
Descriptive data are presented as individual values, mean 
± SD. Sociodemographic and neurological signs differ-
ences between groups were compared using unpaired 
t-test, ANOVA, or chi-square test as appropriate. We 
repeated these comparisons of neurological function 
using ANCOVA to account for potential confounders, 
including age, sex, ethnicity, and IQ. To estimate changes 
in neurological signs over time, we performed a repeated-
measure ANOVA in individuals with both a baseline and 
a follow-up assessment. Correlation analyses were used 
to investigate correlations between factors. A hierarchical 
linear regression was used to explore whether neurolog-
ical signs at baseline predicted functioning at follow-up 
over and above employment status at baseline. All statis-
tical tests were 2-tailed. Statistical analyses were carried 
out using the Statistical Package for Social Sciences ver-
sion 23.
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Results
For 233 patients who had a baseline neurological assess-
ment, there were also data on illness course. Of these, 147 
(63%) fulfilled criteria for a non-remitting course of ill-
ness, and 86 (37%) for a remitting course. Demographic 
and clinical characteristics of both patient groups and 
healthy controls are shown in table 1. The non-remitting 
group included significantly more males than the remitting 
and control groups. Both psychosis groups were slightly 
younger, less likely to be White British, and had a lower 
premorbid and full-scale IQ than controls. Non-remitting 
patients also had a significantly lower premorbid and 
full-scale IQ than remitting patients (table 1). Finally, the 
non-remitting group included a higher proportion of indi-
viduals with a diagnosis of schizophrenia, had more posi-
tive and negative symptoms and less hypomanic symptoms 
at baseline, and had significantly lower GAF-s and GAF-d 
scores at follow-up than the remitting group (table 1).
Approximately 10 years later (mean 9.1 years, SD 2.1), 
we obtained a second neurological assessment in 56 pa-
tients. These individuals were similar to those who only 
had a baseline assessment in premorbid IQ (NART 99 vs 
97, respectively) and illness course (remitting 36% vs 37%, 
respectively) but were slightly younger (28 vs 32 years of 
age), less likely to be White British (48% vs 60%), more 
likely to be males (62% vs 52%), and to have a diagnosis 
of nonaffective psychosis (62% vs 46%). Healthy controls 
were assessed only once at baseline.
Relationship Between Baseline Neurological Signs 
Scores and Illness Course
At baseline, individuals who subsequently became non-
remitting already showed significantly more neurological 
signs than both remitting individuals and controls. The 
one-way ANOVA identified significant between-group 
differences for Primary (F  =  15.3; df  =  2; P < .001), 
Motor Coordination (F = 48.1; df = 2, P < .001), Motor 
Sequencing (F = 5.4; df = 2; P = .005), and Total signs 
(F = 27.1; df = 2; P < .001). The post hoc analysis revealed 
that this was due to the non-remitting group showing 
higher scores than the remitting group for Primary 
(P  =  .030), Motor Coordination (P  =  .001), and Total 
signs (P = .001) than the remitting group. Furthermore, 
the non-remitting group also showed higher scores than 
controls for Primary (P < .001), Motor Coordination (P 
< .001), Motor Sequencing (P = .003), and Total signs (P 
< .001). In contrast, individuals who became remitting 
had more signs than controls on Motor Coordination (P 
< .001) and Total signs (P = .020). There were no differ-
ences in antipsychotic side-effects (table 2).
To ensure that differences in neurological function 
between groups were not influenced by age, gender, eth-
nicity, or IQ (premorbid and current), we performed a 
2-way ANCOVA analysis using group membership, 
gender, and ethnicity as fixed factors and age and IQ 
as covariates. This analysis showed that there was still a 
significant effect of group for Primary signs (F  =  10.4; 
df = 2; P < 0.001), Motor Coordination (F = 27.7; df = 2; 
P < 0.001), and Total signs (F = 14; df = 2; P < 0.001). 
The post hoc analysis confirmed that even when these 
factors were taken into account, the non-remitting group 
still had more Primary, Motor Coordination, and Total 
neurological signs at baseline than both remitting individ-
uals (P = .020, P = .003, and P = .002, respectively) and 
healthy controls (P < .001). As there were more patients 
with a diagnosis of schizophrenia in the non-remitting 
group, we compared neurological signs between patients 
with schizophrenia, affective psychoses, and other psych-
oses and found no significant differences in mean scores 
between groups (all P > .2). This suggests that it is un-
likely that the higher neurological signs in non-remitting 
patients were due to the higher proportion of patients 
with schizophrenia in this group.
Finally, we conducted an additional exploratory hi-
erarchical regression analysis to examine neurological 
signs ability to also predict functional outcome (GAF-d 
scores) over and above baseline employment status (a 
proxy measure of baseline functioning). Employment 
status at baseline accounted for 15.1% (R2  =  .151; P < 
.001) of the variation in GAF score at follow-up, and 
adding total neurological signs to the model increased 
variance to 17.7% (R2 = .177; delta R2 = .026, F = 5.56, 
F change P  =  .019), suggesting that neurological signs 
at presentation are also predictive of functional and not 
only clinical outcomes.
Longitudinal Changes in Neurological Signs Over the 
First 10 Years of Illness
The neurological signs scores for the 56 subjects who 
completed the 2-time points neurological evaluations 
are presented in table  3. Of these, 36 (64%) were clas-
sified as non-remitting, and 20 (36%) were classified as 
remitting. To assess changes in neurological signs over 
the first 10  years of illness, we performed a repeated 
measure ANOVA with time as within-subject factor and 
group (non-remitting and remitting) as between-subject 
factor. Both non-remitting and remitting groups showed 
an increase in score over time for Primary (time effect 
F = 8.5; df = 1; P = .005), Sensory Integration (time ef-
fect F = 5.9; df = 1; P = .02) and Total signs (time effect 
F  =  7.9; df  =  1, P  =  .007). No significant change over 
time was observed for Motor Coordination signs in the 2 
groups (time effect F = 0.07; df = 1; P = .1; time × group 
effect F = 0.17; df = 1; P = .6). Interestingly, there was a 
nonsignificant increase in Motor Sequencing signs only 
in the non-remitting group (time × group effect F = 4.9, 
df = 1, P = .031). There were no between-group or time 
differences in the course of Barnes, Simpson–Angus, or 
AIMS mean scores.
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Table 1. Demographic and clinical characteristics of patients and controls
Characteristic
Non-remitting  
patients  
n = 147
Remitting  
patients  
n = 86
Controls  
n = 172 P (t-test/ANOVA/x2)
Female gender, n (%) 58 (40) 47 (55) 91 (53)  .02 (x2 = 7.5; df = 2)a
Age years, median (interquartile range) 29 (21–38) 28.5 (24–38) 35 (27–47) <.00b (F = 11.3; df = 2) 
Handedness, n (% right)c 130 (89) 80 (93) 154 (91) NS (x2 = 1.1; df = 2)
Ethnicity, n (%):    <.001d (x2 = 21.1; df = 2)
 White British 79 (54) 54 (63) 134 (78)  
 Black and Minority ethnic 68 (46) 32 (37) 38 (22)  
Premorbid IQ, mean NART (SD)e 94. 91 (14.12) 101.78 (13.97) 106.74 (11.95) <.001 (F = 26.8; df = 2)
Current full-scale IQ, mean WAIS-R (SD)f 85.95 (14.39) 95.92 (17.32) 105.30 (14.61) <.001 (F = 55.0; df = 2)
Duration of untreated illness, weeks median  
(interquartile range)g
21 (5–71) 3 (1–6) — <.001 (t = 9.0; df = 204)
Duration of illness, weeks median  
(interquartile range)h
39 (17–94) 14 (9–29) — <.001 (t = 5.1; df = 195)
Lifetime diagnosis, n (%):   — <.001i (x2 = 37.3; df = 2)
Schizophrenia 82 (56) 16 (19)
Affective psychosis 34 (23) 51 (59)   
Other psychosis 31(21) 20 (23)   
SCAN symptoms, mean (SD)j   
 Positive 6.41 (4.43) 4.51 (3.47)  .001 (t = 3.3; df = 167)
 Depressive 1.43 (2.08) 1.22 (1.52)  NS (t = 0.7; df = 195)
 Hypomania 0.82 (1.54) 2.45 (2.69)  <.001 (t = −4.6; df = 91)
 Negative 0.55 (0.73) 0.25 (0.53)  0.001 (t = 3.31; df = 176)
 Total 11.79(6.07) 10.26 (5.41)  NS (t = 1.7; df = 195)
Negative symptoms during follow-up, n (%)k 49 (18) 5 (6) — <.001 (x2 = 21; df = 1)
Antipsychotics at baseline assessment, n (%)l   — NS (x2 = 3.9; df = 3)
 First generation 61 (50) 35 (47)   
 Second generation 38 (31) 19 (26)   
 Both first and second generation 2 (2) 0 (0)   
 Drug naïve or drug free 21 (17) 20 (27)   
Chlorpromazine equivalents at  
baseline assessment, mean (SD)
185.3 (167.5) 174 (196.8) — NS (t = 0.4; df = 168)
Weeks on antipsychotics during  
follow-up, mean (SD) 
287.1 (200) 153.8 (210)  <.001 (t = 3.8; df = 147)
Time adherent to medications  
over follow up (n, %)
  — NS (x2 = 3.6; df = 2)
 0–33% 20 (19) 5 (8)   
 34–67% 24 (22) 13 (21)   
 68–100% 64 (59) 43 (71)   
GAF-s, mean (SD)m 55.29 (18.52) 74.59 (12.7) — <.001 (t = −8.4; df = 178)
GAF-d, mean (SD) 51.91 (17.46) 71.63 (15.65)  <.001 (t = −7.5; df = 176)
Note: GAF, Global Assessment of Functioning; IQ, intelligence quotient; NART, National Adult Reading Test; NS, not significant; SCAN, Schedules for 
Clinical Assessment in Neuropsychiatry; WAIS-R, Wechsler Adult Intelligence Scale.
aPost hoc analysis: non-remitting individuals had a significantly lower percentage of females than remitting individuals and controls (P = .04 and P = .02, 
respectively).
bPost hoc analysis: controls were significantly older than non-remitting (P < .001) and remitting (P = .001) individuals. There were no age differences be-
tween non-remitting and remitting individuals.
cInformation on handedness was obtained for 146 people in the non-remitting group, 86 in the remitting group, and 169 controls.
dPost hoc analysis: controls had significantly more individuals of white ethnicity compared to non-remitting (P < .001) and remitting (P = .015) individ-
uals.
eInformation on NART IQ was obtained for 109 people in the non-remitting, 67 people in the remitting group, and 164 controls. Post hoc analysis: con-
trols had a significantly higher NART IQ than remitting (P = .025) and non-remitting individuals (P < .001). Moreover, non-remitting individuals had a 
significantly lower IQ than remitting individuals (P < .002).
fInformation on WAIS-R IQ was obtained for 114 non-remitting individuals, 70 remitting individuals, and 162 controls. Post hoc analysis: controls had 
a significantly higher total IQ than remitting (P < .001) and non-remitting individuals (P < 0.001). Furthermore, non-remitting individuals had a signifi-
cantly lower IQ than remitting individuals (P < .001).
gInformation on duration of untreated illness was obtained for 145 non-remitting individuals and 83 remitting individuals. The distribution of duration of 
untreated illness was highly skewed and, therefore, logarithmic transformation was used to compare it across the 2 groups using a parametric test.
hInformation on duration of illness was obtained for 123 non-remitting individuals and 74 remitting individuals. The distribution of duration of untreated 
illness was highly skewed and, therefore, logarithmic transformation was used to compare it across the 2 groups using a parametric test.
iPost hoc analysis: the non-remitting group included more individuals with a diagnosis of schizophrenia (P < .001) and other psychosis (P = .005) than the 
remitting group.
jSymptom details were missing for 18 non-remitting individuals and 18 remitting individuals.
kData on the presence of negative symptoms during the follow-up period were available for 141 non-remitting individuals and for 82 remitting individuals.
lInformation on antipsychotic medications at baseline neurological evaluation was available for 196 patients.
mGAF-s scores were available for 118 non-remitting individuals and 68 remitting individuals, and GAF-d scores for 114 non-remitting individuals and for 
64 remitting individuals.
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Relationship With Antipsychotic Medications
We explored the potential role of  antipsychotic medi-
cations in explaining neurological signs rates. We found 
no differences in the proportion of  non-remitting and 
remitting patients taking first- or second-generation 
antipsychotics, being drug-free or naïve at baseline, 
nor in antipsychotic dose (table 1). Furthermore, there 
was no correlation between baseline antipsychotic dose 
and baseline neurological signs or between number of 
weeks on medications and neurological signs at fol-
low-up (table  4). This suggests that between-group 
differences in baseline neurological signs and change 
in signs over time are unlikely to be related to antipsy-
chotic exposure.
Discussion
To the best of  our knowledge, this is the first prospective 
study that has investigated the relationship between dif-
ferent domains of neurological signs at illness onset and 
long-term illness course and functional outcome, as well 
as change over the first 10 years of  illness in a large sample 
of individuals with first-episode psychosis. Our main 
finding is that, at their first presentation to services, those 
Table 3. Neurological signs and side effect scales mean scores at baseline and at follow-up in patients with non-remitting and remitting 
course of illness (ANOVA)
Scale, mean (SD)
Non-remitting  
patients  
n = 36
Remitting  
patients  
n = 20 Time effect
Time × group  
effect
Baseline Follow-up Baseline Follow-up P (F; df) P (F; df)
Primary 4.4 (3.7) 7.6 (6.5) 3.9 (3.6) 6.0 (4.6) 0.005  
(8.5; 1)
NS  
(0.3; 1)
Sensory Integration 1.6 (1.8) 2.8 (2.2) 0.7 (1.0) 1.1 (1.6) 0.02  
(5.9; 1)
NS  
(1.3; 1)
Motor Coordination 1.9 (2.0) 1.7 (2.3) 0.8 (1.1) 0.9 (1.0) NS  
(0.07; 1)
NS  
(0.17; 1)
Motor Sequencinga 2.1 (2.3) 3.9 (3.5) 1.2 (1.9) 1.1 (1.3) NS  
(3.5; 1)
0.031  
(4.9; 1)
Total 10.2 (7.3) 15.3 (11.0) 6.5 (6.0) 9.0 (5.5) 0.007  
(7.9; 1)
NS  
(0.96; 1)
Tardive dyskinesia, AIMSa 0.21 (0.5) 0.37 (1.6) 0.47 (0.91) 0.07 (0.26) NS  
(0.3;1)
NS  
(1.6;1)
Akathisia, Barnesa 1.2 (2.3) 2.1 (2.7) 1.1 (2.0) 0.7 (1.8) NS  
(0.23;1)
NS  
(1.9;1)
Extrapyramidal symptoms,  
Simpson–Angusa
2.3 (2.8) 3.9 (7.1) 1.1 (1.1) 0.6 (1.4) NS  
(0.3; 1)
NS  
(1.0; 1)
Note: AIMS, Abnormal Involuntary Movement in Schizophrenia Scale; NS, not significant; bold P values indicate significance values <.05.
aMotor sequencing score for missing for 1 patient; AIMS scores were available for 40 patients, Barnes scores for 45 patients, and 
Simpson–Angus scores for 38 patients.
Table 2. Neurological signs and side-effect scales mean scores at baseline
Scale
Non-remitting  
patients  
n = 147
Remitting  
patients  
n = 86
Controls  
n = 172
Statistical  
significance
Neurological signs, mean (SD); (quartiles)     
 Primary 3.9 (4.0); (1 3 6) 2.8 (2.9); (0 2 4) 2.0 (2.2); (0 1 3) <.001 (F = 15.3; df = 2)
 Sensory Integration 1.5 (1.9); (0 1 2) 1.1 (1.4); (0 0 2) 1.3 (1.5); (0 1 2) NS (F = 1.9; df = 2)
 Motor Coordination 2.6 (2.8); (0 2 4) 1.6 (1.8); (0 1 3) 0.4 (0.9); (0 0 0) <.001 (F = 48.1; df = 2)
 Motor Sequencing 2.2 (2.4); (0 2 4) 1.7 (2.1); (0 1 3) 1.5 (1.7); (0 1 2)  .005 (F = 5.4; df = 2)
 Total  10.2 (8.2); (5 9 15) 7.3 (5.7); (3 6 10) 5.1 (3.9); (2 4 8) <.001 (F = 27.1; df = 2)
Tardive dyskinesia, mean AIMS (SD) 0.7 (2.2) 0.6 (1.6) — NS (t = 0.4; df = 220)
Akathisia, mean Barnes (SD) 1.3 (2.3) 1.5 (2.7) — NS (t = −0.6; df = 221)
Extrapyramidal symptoms, Simpson–Angus 
mean (SD)
2.2 (3.3) 1.3 (1.6) — .008 (t = 2.7; df = 218)
Note: AIMS, Abnormal Involuntary Movement in Schizophrenia Scale; NS, not significant.
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patients who subsequently develop a more severe illness 
course (non-remitting) already show significantly more 
Primary, Motor Coordination, and Total signs than both 
those who follow a more favorable course (remitting) 
and healthy controls, even when correcting for potential 
confounders, such as cognitive ability. This suggests that 
certain domains of neurological impairment represent 
early markers of  a more severe illness type. Our second 
main finding is that, independently of  illness course type, 
impairments in Motor Coordination remain stable over 
time and represent a trait-like feature of  psychosis, while 
deficits in Primary, Sensory Integration, and Total signs 
worsen, suggesting they reflect illness duration.
This study advances our previous findings that, at first 
presentation, only Primary and Motor Coordination 
signs are specific to the presence of psychosis,47 showing 
that their higher rates at onset characterize those pa-
tients who develop a poorer illness course with worse 
functioning, possibly reflecting a more severe patho-
physiological process. In addition, we find that Motor 
Coordination signs remain stable over time, likely rep-
resenting illness traits. Indeed, this is consistent with re-
ports from shorter follow-ups that motor signs change 
little over 1, 2, 3, and 5 years and even across the lifespan 
in patients with schizophrenia,18,48–50 that they predict 
poorer functional outcomes,51 and that distinct sensori-
motor performance profiles may be even markers of risk 
for psychosis.52 Motor coordination with abnormal invol-
untary movements and catatonia could represent a senso-
rimotor dimension that cuts across psychopathology and 
that has etiological and prognostic value as a psychosis 
endophenotype.28,53 As such, sensorimotor function be-
came one of the Research Domain Criteria (RDoC) in 
2019. As neurological soft signs reflect the integration 
of multiple rather than focal processes, they could well 
be considered abnormalities in any of the sensorimotor 
RDoC subconstructs, involving action planning, initi-
ation, sensorimotor dynamics, execution, or inhibition. 
The recognition of sensorimotor dysfunction could help 
the identification and stratification of patients based on 
an objective, quantifiable measure that could inform clin-
ical management and advance the investigation of the 
neurobiological correlates of psychoses subtypes.
In this regard, our group and others have shown that 
sensorimotor coordination deficits represent the expres-
sion of underlying cortical and subcortical brain alter-
ations specifically associated with the pathophysiology of 
psychosis.6,28 Furthermore, while worse motor coordina-
tion has been linked with anterior cingulate-caudate ab-
errant connectivity, catatonia and dyskinesia have been 
associated with thalamocortical connectivity, suggesting 
that sensorimotor abnormalities are linked to multiple 
pathophysiological mechanisms.54 Finally, recent evidence 
that volume alterations co-occur with aberrant brain ac-
tivity in cortical and cerebellar systems subserving sen-
sory- and psychomotor organization adds to the concept 
of sensorimotor dysfunctions as potential biomarkers for 
psychosis.14 As such, it is not surprising that motor coor-
dination problems would be associated with more severe 
manifestations of the disease.
While there are no previous long-term studies that 
have investigated subgroups of  neurological signs, our 
findings are consistent with only 2 studies with a 10-year 
follow-up, which showed that total neurological signs 
predict poorer psychosocial functioning,15 particularly 
in patients with schizophrenia,16 and service depend-
ency.16 Similar evidence also comes from shorter and 
medium-term follow-ups of  first-episode psychosis pa-
tients. For example, a decrease in neurological signs 
over the first year of  illness has been associated with 
better clinical24,25 and functional outcomes24 and with 
less prominent negative symptoms, a potential indi-
cator of  illness severity.19 Furthermore, higher baseline 
neurological signs at onset have also been found to pre-
dict lack of  treatment response as early as 6 weeks55 
and even 1 year after illness onset.15 Finally, even when 
evaluated before illness onset, neurological signs in 
individuals at ultra-high risk of  psychosis have been 
found to predict illness transition to the illness, as well 
as the onset of  severe negative symptoms 12  months 
later.4
Another interesting finding in our study is that rates 
of sensory integrative signs at baseline do not differ be-
tween non-remitting and remitting groups, nor from 
healthy controls. This advances our previous report of a 
similar sensory integration performance in patients with 
psychosis and controls, showing also that these signs are 
not markers of subsequent illness course and that they 
increase over time in both patients groups, possibly re-
flecting aging rather than illness severity.47,56 Indeed, this 
Table 4. Correlations between neurological signs scores and 
antipsychotics
Correlation between baseline  
neurological signs scores and  
chlorpromazine equivalents  
(mg)
Pearson  
r 
Significance  
P
Primary signs .073 .34
Sensory Integration signs .05 .48
Motor Coordination signs .07 .38
Motor Sequencing signs −.05 .50
Total signs .06 .47
Correlation between  
follow-up neurological 
signs scores and time on 
 antipsychotics during the 
 follow-up (weeks)
Pearson  
r
Significance  
P
Primary signs .065 .65
Sensory Integration signs .23 .1
Motor Coordination signs −.05 .74
Motor Sequencing signs .005 .97
Total signs .004 .79
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may also be the case for Primary signs, which we found 
to also increase over time in both remitting and non-
remitting patients.
In contrast, only Motor Sequencing signs increased 
over time in patients with a non-remitting course. It is dif-
ficult to interpret this finding, which is consistent, at least 
in part, with reports that an increase or lack of change in 
function is present in patients with worse outcomes and 
a reduction in those with a more episodic course.23,57 In 
fact, in the few studies that reported an overall increase 
in neurological impairment after a first psychotic episode, 
this increase was mostly seen in the subgroup of patients 
with a worse clinical course.20,22,58 Taken together, these 
findings support the hypothesis that different sensori-
motor signs represent a combination of trait- and state-
like illness features.
Critical to the interpretation of neurological and par-
ticularly sensorimotor signs in psychosis is the evaluation 
of their relationship with antipsychotic use. Our findings, 
however, confirm previous reports from us and others2,47,59 
that sensorimotor abnormalities represent an intrinsic 
feature of psychoses and are not related to medications 
use.53 Here, we evaluated neurological signs at baseline, 
prior to long-term exposure to antipsychotics, and found 
no differences in the type or dose of antipsychotic in 
non-remitting and remitting patients, nor any correlation 
between antipsychotic exposure and neurological perfor-
mance at the 10-year follow-up. This makes our results 
even stronger, showing that differences in neurological 
performance between patients who develop different ill-
ness trajectories are unlikely to result from differences in 
antipsychotic treatment.
The present study has several strengths, particularly 
the large sample size with neurological function evalu-
ated at baseline and the long follow-up period. The evalu-
ation of clinical outcome over a long period of time, with 
a standardized instrument allowed us to investigate neu-
rological function as an early marker of poor long-term 
illness outcome. Although we could evaluate changes in 
neurological function only in a subset of patients, we pro-
vide here the first report of long-term changes that follow 
the first episode of psychosis. This should be evaluated 
in larger clinical populations in parallel with other illness 
indicators. We cannot exclude the possibility of selection 
bias as, in longitudinal studies, those patients more likely 
to be traced could be those with a more severe illness type 
and worse functional outcome. However, the sample with 
baseline neurological function and illness course data we 
included here was similar to the AESOP-10 core sample 
for age, sex, and illness course and included slightly less 
individuals with a diagnosis of schizophrenia.31 While, 
here, we had more patients with schizophrenia in the 
non-remitting group, as in our previous report,47 we 
found no differences in neurological function across di-
agnostic groups, suggesting that neurological signs are a 
marker of illness course rather than diagnosis. Finally, 
while psychotropic substances, such as cannabis or am-
phetamines, could also affect neurological function, the 
proportion of patients with lifetime cannabis or amphet-
amines use was similar in the non-remitting and remit-
ting group (34% vs 37% for amphetamines and 88% vs 
86% for cannabis, respectively), making it unlikely that 
substance use patterns could explain motor coordination 
signs differences between groups.
In conclusion, we suggest that some neurological ab-
normalities, specifically motor coordination problems, 
could be a useful early, quick, and easily detectable in-
dicator of subsequent clinical outcome that could help 
stratify patients early in the illness, identifying those who 
might benefit from a particularly assertive treatment. 
From a therapeutic perspective, the presence of senso-
rimotor abnormalities could also inform the choice of 
antipsychotics, including consideration for clozapine as 
appropriate, given its possible beneficial effects on senso-
rimotor dysfunction and favoring an approach focused 
not only on symptomatic improvement but also on lim-
iting sensorimotor abnormalities that may hamper social 
functioning in the community.
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